CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

China's Asymchem Q3 revenue, net profit rise on macromolecules strength

By Reuters News


Overview

  • China CDMO's Q3 revenue rose 24% yr/yr to RMB 1.79 bln

  • Net profit attributable to shareholders increased 81.5% yr/yr

  • Growth driven by chemical macromolecules, biological macromolecules, and drug product segments


Outlook

  • Company expects full-year 2026 operating revenue to increase by 19% to 22%

  • Q4 delivery scale is expected to increase significantly versus Q3, supported by its order backlog


Result Drivers

  • MACROMOLECULAR SEGMENTS - Co said Q3 growth was mainly driven by strong performance in chemical macromolecules, biological macromolecules, and drug product segments

  • EMERGING BUSINESS GROWTH - Revenue from emerging businesses rose sharply, with gross profit margin of 30.95% in Q3

  • OPERATING EFFICIENCY - Co said shift to 'cost control and efficiency improvement' approach enhanced profitability and competitiveness


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

RMB 1.79 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Asymchem Laboratories (Tianjin) Co Ltd is CNY191.70, about 37.3% above its October 22 closing price of CNY139.66

  • The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 37 three months ago


Reuters Recommended Reads

  • Oct 20 - Medical products distributor Sinopharm Group's prelim 9-month revenue slips

  • Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised

  • Oct 21 - Integra Lifesciences Q3 revenue slightly misses estimates on flood damage


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


Press Release https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1022/2026102200811.pdf

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.